Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jennifer Newman
Observed names:
J. Newman,
Jennifer J. Newman
Institution:
Memorial Sloan Kettering Cancer Center
Observed institutions:
New York State Department of Health,
Boehringer Ingelheim (Germany),
Memorial Sloan Kettering Cancer Center,
Royal Cornwall Hospital,
London Health Sciences Centre,
Massachusetts General Hospital,
Victoria Hospital,
Boehringer Ingelheim (United States)
show all 8
OpenAlex ID:
A5111979092
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
·
Bernard Zinman
, Silvio E Inzucchi
, et al.
·
Cardiovascular Diabetology
·
239
PDF
Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment
2012
·
Janet B. McGill
, Lance Sloan
, et al.
·
Diabetes Care
·
204
37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3)
2017
·
And Sepsis Study Group
, M. Von Seth
, et al.
·
Critical Care
·
48
PDF
Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis
2013
·
Sonja C. Sawh
, Jennifer J. Newman
, et al.
·
PeerJ
·
15
PDF
Challenges Associated with Investigating Salmonella Enteritidis with Low Genomic Diversity in New York State: The Impact of Adjusting Analytical Methods and Correlation with Epidemiological Data
2023
·
Deborah J. Baker
, Amy Robbins
, et al.
·
Foodborne Pathogens and Disease
·
11
PDF
Aberrant Somatic Hypermutation Plays Minor Role in the Evolution of Molecular Alterations at Recurrence in PCNSL (P8-6.010)
2025
·
Jennifer Newman
, Lauren Schaff
, et al.
·
Neurology
Summary of nonclinical data for gene therapy developmental candidate HMI-203 for mucopolysaccharidosis type II (MPS II, or Hunter syndrome)
2022
·
Laura J. Smith
, Kruti Patel
, et al.
·
Molecular Genetics and Metabolism
HMI-203: Gene therapy developmental candidate for mucopolysaccharidosis type II (MPS II), or Hunter syndrome
2021
·
Kruti Patel
, Laura Smith
, et al.
·
Molecular Genetics and Metabolism
HMI-202: A gene therapy development candidate for metachromatic leukodystrophy (MLD)
2021
·
Jacinthe Gingras
, Thia St-Martin
, et al.
·
Molecular Genetics and Metabolism
Patients Sith Diarrhea-Predominant Irritable Bowel Syndrome Have Lower Disease-Specific Quality of Life Than Constipation-Predominant Irritable Bowel Syndrome
2014
·
Prashant Singh
, Kyle Staller
, et al.
·
The American Journal of Gastroenterology
P305 Linagliptin fournit une efficacité similaire au glimépiride mais améliore la sécurité cardiovasculaire à 2 ans chez des Patients atteints de diabète de Type 2 insuffisamment contrôlés par metformine
2012
·
L. Sloan
, J. Newman
, et al.
·
Diabetes & Metabolism
P306 L’innocuité et l’efficacité de la Linagliptine chez des patients diabétiques de type 2 avec une insuffisance rénale sévère
2012
·
L. Sloan
, J. Newman
, et al.
·
Diabetes & Metabolism
Empiric Antibiotic Prescribing Practice in Febrile Neutropenia: Compliance with IDSA Guidelines
2001
·
Jennifer Newman
, Cheryl M Thompson
, et al.
·
The Canadian Journal of Hospital Pharmacy
PDF
The Role of Dornase Alfa in the Treatment of Severe Cystic Fibrosis
2001
·
Jennifer Newman
, Charles D. Bayliff
, et al.
·
The Canadian Journal of Hospital Pharmacy
PDF
Drug Interaction between Ticlopidine and Cyclosporine
2001
·
Uchenwa Iroaga
, Jennifer Newman
, et al.
·
The Canadian Journal of Hospital Pharmacy
PDF
Show more works
View as search
Works count:
15
Citation count:
517
H-index:
5
I10-index:
5
Year
Topic
Type